Use of statins in lower extremity artery disease: a review

详细信息    查看全文

• 作者：Giuseppe Gargiulo (1)
  Giuseppe Giugliano (1)
  Linda Brevetti (1)
  Anna Sannino (1)
  Gabriele Giacomo Schiattarella (1)
  Federica Serino (1)
  Andreina Carbone (1)
  Fernando Scudiero (1)
  Marco Ferrone (1)
  Roberto Corrado (1)
  Raffaele Izzo (1)
  Lorenzo Chiariotti (2)
  Cinzia Perrino (1)
  Bruno Amato (3)
  Bruno Trimarco (1)
  Giovanni Esposito (1)
  
• 刊名：BMC Surgery
• 出版年：2012
• 出版时间：November 2012
• 年：2012
• 卷：12
• 期：1-supp
• 全文大小：117KB
• 参考文献：1. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, / et al.: ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). / Eur Heart J 2011,32(22):2851鈥?906. CrossRef
  2. Giugliano G, Di Serafino L, Perrino C, Schiano V, Laurenzano E, Cassese S, De Laurentis M, Schiattarella GG, Brevetti L, Sannino A, / et al.: Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease. / Int J Cardiol 2012.
  3. Schiano V, Sirico G, Giugliano G, Laurenzano E, Brevetti L, Perrino C, Brevetti G, Esposito G: Femoral plaque echogenicity and cardiovascular risk in claudicants. / JACC Cardiovasc Imaging 2012,5(4):348鈥?57. CrossRef
  4. Perrino C, Gargiulo G, Pironti G, Franzone A, Scudiero L, De Laurentis M, Magliulo F, Ilardi F, Carotenuto G, Schiattarella GG, / et al.: Cardiovascular effects of treadmill exercise in physiological and pathological preclinical settings. / Am J Physiol Heart Circ Physiol 2011,300(6):H1983鈥?989. CrossRef
  5. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G, / et al.: Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. / Nat Med 1995,1(6):541鈥?45. CrossRef
  6. Indolfi C, Avvedimento EV, Di Lorenzo E, Esposito G, Rapacciuolo A, Giuliano P, Grieco D, Cavuto L, Stingone AM, Ciullo I, / et al.: Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. / Nat Med 1997,3(7):775鈥?79. CrossRef
  7. Indolfi C, Stabile E, Perrino C, Chiariello M: Mechanisms of restenosis after angioplasty and approach to therapy (Review). / Int J Mol Med 1998,2(2):143鈥?48.
  8. Iaconetti C, Polimeni A, Sorrentino S, Sabatino J, Pironti G, Esposito G, Curcio A, Indolfi C: Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. / Basic Res Cardiol 2012,107(5):296. CrossRef
  9. Indolfi C, Torella D, Cavuto L, Davalli AM, Coppola C, Esposito G, Carriero MV, Rapacciuolo A, Di Lorenzo E, Stabile E, / et al.: Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. / Circulation 2001,103(24):2980鈥?986. CrossRef
  10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial / Lancet 2002,360(9326):7鈥?2.
  11. Knopp RH, d'Emden M, Smilde JG, Pocock SJ: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). / Diabetes Care 2006,29(7):1478鈥?485. CrossRef
  12. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A, Leccia A, Cavuto L, Stingone AM, Chieffo A, / et al.: Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. / J Am Coll Cardiol 2000,35(1):214鈥?21. CrossRef
  13. Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D, Cittadini A, Cardone L, Coppola C, Cavuto L, / et al.: Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. / Circulation 2002,106(16):2118鈥?124. CrossRef
  14. Perrino C, Schiattarella GG, Magliulo F, Ilardi F, Carotenuto G, Gargiulo G, Serino F, Ferrone M, Scudiero F, Carbone A, / et al.: Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management. / Curr Vasc Pharmacol 2012.
  15. Aronow WS, Ahn C: Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. / Am J Cardiol 2002,90(7):789鈥?91. CrossRef
  16. Schillinger M, Exner M, Mlekusch W, Amighi J, Sabeti S, Muellner M, Rumpold H, Wagner O, Minar E: Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. / Eur Heart J 2004,25(9):742鈥?48. CrossRef
  17. Feringa HH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, Galal W, Vidakovic RV, Tangelder MJ, Poldermans D: Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. / J Am Coll Cardiol 2006,47(6):1182鈥?187. CrossRef
  18. de Groot E, Jukema JW, van Boven AJ, Reiber JH, Zwinderman AH, Lie KI, Ackerstaff RA, Bruschke AV: Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. / Am J Cardiol 1995,76(9):40C-46C. CrossRef
  19. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS: Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. / Eur J Vasc Endovasc Surg 2009,38(4):463鈥?74. CrossRef
  20. Erez G, Leitersdorf E: The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease. / Eur J Vasc Endovasc Surg 2007,33(2):192鈥?01. CrossRef
  21. Pedersen TR, Kjekshus J, Pyorala K, Olsson AG, Cook TJ, Musliner TA, Tobert JA, Haghfelt T: Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). / Am J Cardiol 1998,81(3):333鈥?35. CrossRef
  22. Vidula H, Tian L, Liu K, Criqui MH, Ferrucci L, Guralnik JM, Green D, Ridker P, McDermott MM: Comparison of effects of statin use on mortality in patients with peripheral arterial disease with versus without elevated C-reactive protein and d-dimer levels. / Am J Cardiol 2010,105(9):1348鈥?352. CrossRef
  23. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, Pastore M, Borrello F, Belcastro M, Picchi A, / et al.: Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. / Am J Med 2003,114(5):359鈥?64. CrossRef
  24. Mohler ER 3rd, Hiatt WR, Creager MA: Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. / Circulation 2003,108(12):1481鈥?486. CrossRef
  
• 作者单位：Giuseppe Gargiulo (1)
  Giuseppe Giugliano (1)
  Linda Brevetti (1)
  Anna Sannino (1)
  Gabriele Giacomo Schiattarella (1)
  Federica Serino (1)
  Andreina Carbone (1)
  Fernando Scudiero (1)
  Marco Ferrone (1)
  Roberto Corrado (1)
  Raffaele Izzo (1)
  Lorenzo Chiariotti (2)
  Cinzia Perrino (1)
  Bruno Amato (3)
  Bruno Trimarco (1)
  Giovanni Esposito (1)
  
  1. Department of Clinical Medicine and Cardiovascular and Immunology Sciences, Federico II University, via Pansini 5, 80131, Naples, Italy
  2. Department of Biology and Cellular and Molecular Pathology, Federico II University, via Pansini 5, 80131, Naples, Italy
  3. Department of General, Geriatric, Oncologic Surgery and Advanced Technologies, Federico II University, via Pansini 5, 80131, Naples, Italy
  

文摘

Background Lower extremity artery disease (LE-PAD) is one of the most common manifestations of atherosclerosis, particularly in elderly patients, and it is related to a high cardiovascular risk. Description It is well established that statin therapy is characterized by crucial benefits on cardiovascular system by limiting atherosclerotic progression and reducing cardiovascular events and mortality. A growing body of evidence support efficacy of statins in LE-PAD due to the ability of both reducing cardiovascular risk and improving walking distance and, hence, quality of life. Consequently, statin therapy should be considered in all LE-PAD patients and new LDL-cholesterol targets should be reached. Conclusions Our opinion is that statin therapy remains still underutilized or with inadequate dosage, so therapy of LE-PAD patients should be improved to obtain all the demonstrated benefits of statins.